http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103623425-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate | 2012-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103623425-B |
| titleOfInvention | The medicine of application dual-target antagonism widow's nucleic acid suppression neovascularity proliferative disease |
| abstract | The invention discloses the medicine for treating neovascularity proliferative disease, this medicine is with miRNA 132 and miRNA 155 as target spot, utilize two specific antagonist widow nucleic acid antagomir 132, antagomir 155 as the basis of medicine, in focus, strike the acid of low above-mentioned two micronucleus simultaneously, the hyperplasia of new vessels can be suppressed to reach therapeutic effect.For guaranteeing effective use of this medicine, present invention employs internal importing carrier, as histidine lysine polypeptide polymer HKP, part targeting type import nano-granular system RGD PEG HKP, to promote the specificity and efficiency of medicine importing blood vessel hyperplasia position (eye or tumor locus). |
| priorityDate | 2012-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 133.